Cargando…

Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor

OBJECTIVES: Chronic hyperlipidemia and hyperglycemia are characteristic features of type 2 diabetes (T2DM) that are thought to cause or contribute to β-cell dysfunction by “glucolipotoxicity.” Previously we have shown that acute treatment of pancreatic islets with fatty acids (FA) decreases acetylch...

Descripción completa

Detalles Bibliográficos
Autores principales: Doliba, Nicolai M., Liu, Qin, Li, Changhong, Chen, Pan, Liu, Chengyang, Naji, Ali, Matschinsky, Franz M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641685/
https://www.ncbi.nlm.nih.gov/pubmed/29031723
http://dx.doi.org/10.1016/j.molmet.2017.07.017
_version_ 1783271274068312064
author Doliba, Nicolai M.
Liu, Qin
Li, Changhong
Chen, Pan
Liu, Chengyang
Naji, Ali
Matschinsky, Franz M.
author_facet Doliba, Nicolai M.
Liu, Qin
Li, Changhong
Chen, Pan
Liu, Chengyang
Naji, Ali
Matschinsky, Franz M.
author_sort Doliba, Nicolai M.
collection PubMed
description OBJECTIVES: Chronic hyperlipidemia and hyperglycemia are characteristic features of type 2 diabetes (T2DM) that are thought to cause or contribute to β-cell dysfunction by “glucolipotoxicity.” Previously we have shown that acute treatment of pancreatic islets with fatty acids (FA) decreases acetylcholine-potentiated insulin secretion. This acetylcholine response is mediated by M3 muscarinic receptors, which play a key role in regulating β-cell function. Here we examine whether chronic FA exposure also inhibits acetylcholine-potentiated insulin secretion using mouse and human islets. METHODS: Islets were cultured for 3 or 4 days at different glucose concentration with 0.5 mM palmitic acid (PA) or a 2:1 mixture of PA and oleic acid (OA) at 1% albumin (PA/BSA molar ratio 3.3). Afterwards, the response to glucose and acetylcholine were studied in perifusion experiments. RESULTS: FA-induced impairment of insulin secretion and Ca(2+) signaling depended strongly on the glucose concentrations of the culture medium. PA and OA in combination reduced acetylcholine potentiation of insulin secretion more than PA alone, both in mouse and human islets, with no evidence of a protective role of OA. In contrast, lipotoxicity was not observed with islets cultured for 3 days in medium containing less than 1 mM glucose and a mixture of glutamine and leucine (7 mM each). High glucose and FAs reduced endoplasmic reticulum (ER) Ca(2+) storage capacity; however, preserving ER Ca(2+) by blocking the IP3 receptor with xestospongin C did not protect islets from glucolipotoxic effects on insulin secretion. In contrast, an inhibitor of casein kinase 2 (CK2) protected the glucose dependent acetylcholine potentiation of insulin secretion in mouse and human islets against glucolipotoxicity. CONCLUSIONS: These results show that chronic FA treatment decreases acetylcholine potentiation of insulin secretion and that this effect is strictly glucose dependent and might involve CK2 phosphorylation of β-cell M3 muscarinic receptors.
format Online
Article
Text
id pubmed-5641685
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-56416852017-10-23 Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor Doliba, Nicolai M. Liu, Qin Li, Changhong Chen, Pan Liu, Chengyang Naji, Ali Matschinsky, Franz M. Mol Metab Original Article OBJECTIVES: Chronic hyperlipidemia and hyperglycemia are characteristic features of type 2 diabetes (T2DM) that are thought to cause or contribute to β-cell dysfunction by “glucolipotoxicity.” Previously we have shown that acute treatment of pancreatic islets with fatty acids (FA) decreases acetylcholine-potentiated insulin secretion. This acetylcholine response is mediated by M3 muscarinic receptors, which play a key role in regulating β-cell function. Here we examine whether chronic FA exposure also inhibits acetylcholine-potentiated insulin secretion using mouse and human islets. METHODS: Islets were cultured for 3 or 4 days at different glucose concentration with 0.5 mM palmitic acid (PA) or a 2:1 mixture of PA and oleic acid (OA) at 1% albumin (PA/BSA molar ratio 3.3). Afterwards, the response to glucose and acetylcholine were studied in perifusion experiments. RESULTS: FA-induced impairment of insulin secretion and Ca(2+) signaling depended strongly on the glucose concentrations of the culture medium. PA and OA in combination reduced acetylcholine potentiation of insulin secretion more than PA alone, both in mouse and human islets, with no evidence of a protective role of OA. In contrast, lipotoxicity was not observed with islets cultured for 3 days in medium containing less than 1 mM glucose and a mixture of glutamine and leucine (7 mM each). High glucose and FAs reduced endoplasmic reticulum (ER) Ca(2+) storage capacity; however, preserving ER Ca(2+) by blocking the IP3 receptor with xestospongin C did not protect islets from glucolipotoxic effects on insulin secretion. In contrast, an inhibitor of casein kinase 2 (CK2) protected the glucose dependent acetylcholine potentiation of insulin secretion in mouse and human islets against glucolipotoxicity. CONCLUSIONS: These results show that chronic FA treatment decreases acetylcholine potentiation of insulin secretion and that this effect is strictly glucose dependent and might involve CK2 phosphorylation of β-cell M3 muscarinic receptors. Elsevier 2017-08-04 /pmc/articles/PMC5641685/ /pubmed/29031723 http://dx.doi.org/10.1016/j.molmet.2017.07.017 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Doliba, Nicolai M.
Liu, Qin
Li, Changhong
Chen, Pan
Liu, Chengyang
Naji, Ali
Matschinsky, Franz M.
Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor
title Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor
title_full Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor
title_fullStr Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor
title_full_unstemmed Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor
title_short Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor
title_sort inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: protection by casein kinase 2 inhibitor
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641685/
https://www.ncbi.nlm.nih.gov/pubmed/29031723
http://dx.doi.org/10.1016/j.molmet.2017.07.017
work_keys_str_mv AT dolibanicolaim inhibitionofcholinergicpotentiationofinsulinsecretionfrompancreaticisletsbychronicelevationofglucoseandfattyacidsprotectionbycaseinkinase2inhibitor
AT liuqin inhibitionofcholinergicpotentiationofinsulinsecretionfrompancreaticisletsbychronicelevationofglucoseandfattyacidsprotectionbycaseinkinase2inhibitor
AT lichanghong inhibitionofcholinergicpotentiationofinsulinsecretionfrompancreaticisletsbychronicelevationofglucoseandfattyacidsprotectionbycaseinkinase2inhibitor
AT chenpan inhibitionofcholinergicpotentiationofinsulinsecretionfrompancreaticisletsbychronicelevationofglucoseandfattyacidsprotectionbycaseinkinase2inhibitor
AT liuchengyang inhibitionofcholinergicpotentiationofinsulinsecretionfrompancreaticisletsbychronicelevationofglucoseandfattyacidsprotectionbycaseinkinase2inhibitor
AT najiali inhibitionofcholinergicpotentiationofinsulinsecretionfrompancreaticisletsbychronicelevationofglucoseandfattyacidsprotectionbycaseinkinase2inhibitor
AT matschinskyfranzm inhibitionofcholinergicpotentiationofinsulinsecretionfrompancreaticisletsbychronicelevationofglucoseandfattyacidsprotectionbycaseinkinase2inhibitor